Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Published

Journal Article

The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed by transurethral resection of the prostate.The PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH). The primary end point was death from prostate cancer.The PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate analysis (hazard ratio (HR)=3.51; 95% CI 2.60-4.73; P=3.1 × 10(-14)). It was highly predictive of prostate cancer death in the 50% of patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR=7.4; 95% CI 2.2-24.6; P=0.012) ), but had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (κ=0.5). Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in the multivariate analyses.In low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.

Full Text

Cited Authors

  • Cuzick, J; Yang, ZH; Fisher, G; Tikishvili, E; Stone, S; Lanchbury, JS; Camacho, N; Merson, S; Brewer, D; Cooper, CS; Clark, J; Berney, DM; Møller, H; Scardino, P; Sangale, Z; Transatlantic Prostate Group,

Published Date

  • June 2013

Published In

Volume / Issue

  • 108 / 12

Start / End Page

  • 2582 - 2589

PubMed ID

  • 23695019

Pubmed Central ID

  • 23695019

Electronic International Standard Serial Number (EISSN)

  • 1532-1827

International Standard Serial Number (ISSN)

  • 0007-0920

Digital Object Identifier (DOI)

  • 10.1038/bjc.2013.248

Language

  • eng